• 1
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 2
    Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 3750.
  • 3
    Reveille JD, Solomon DH, and the American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49: 399412.
  • 4
    Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986; 13: 9116.
  • 5
    Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196203.
  • 6
    Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 15467.
  • 7
    Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I: a study of 355 patients. Arthritis Rheum 1988; 31: 37885.
  • 8
    Diot E, Giraudeau B, Diot P, Degenne D, Ritz L, Guilmot JL, et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999; 116: 71520.
  • 9
    Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr. A comparison between anti-Th/To– and anticentromere antibody–positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003; 48: 2039.
  • 10
    Renaudineau Y, Revelen R, Levy Y, Salojin K, Gilburg B, Shoenfeld Y, et al. Anti-endothelial cell antibodies in systemic sclerosis. Clin Diagn Lab Immunol 1999; 6: 15660.
  • 11
    Marks RM, Czerniecki M, Andrews BS, Penny R. The effects of scleroderma serum on human microvascular endothelial cells: induction of antibody-dependent cellular cytotoxicity. Arthritis Rheum 1988; 31: 152434.
  • 12
    Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000; 43: 255062.
  • 13
    Chizzolini C, Raschi E, Rezzonico R, Testoni C, Mallone R, Gabrielli A, et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002; 46: 160213.
  • 14
    Henault J, Tremblay M, Clement I, Raymond Y, Senecal JL. Direct binding of anti–DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 2004; 50: 326574.
  • 15
    Ronda N, Gatti R, Giacosa R, Raschi E, Testoni C, Meroni PL, et al. Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. Arthritis Rheum 2002; 46: 1595601.
  • 16
    Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98: 78592.
  • 17
    LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974; 54: 8809.
  • 18
    Strehlow D, Korn JH. Biology of the scleroderma fibroblast. Curr Opin Rheumatol 1998; 10: 5728.
  • 19
    Trojanowska M, LeRoy EC, Eckes B, Krieg T. Pathogenesis of fibrosis: type 1 collagen and the skin. J Mol Med 1998; 76: 26674.
  • 20
    Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma [letter]. Arthritis Rheum 2001; 44: 7356.
  • 21
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 22
    Senecal JL, Rauch J, Grodzicky T, Raynauld JP, Uthman I, Nava A, et al. Strong association of autoantibodies to human nuclear lamin B1 with lupus anticoagulant antibodies in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 134753.
  • 23
    Auger FA, Lopez Valle CA, Guignard R, Tremblay N, Noel B, Goulet F, et al. Skin equivalent produced with human collagen. In Vitro Cell Dev Biol Anim 1995; 31: 4329.
  • 24
    Hebert MJ, Gullans SR, Mackenzie HS, Brady HR. Apoptosis of endothelial cells is associated with paracrine induction of adhesion molecules: evidence for an interleukin-1β-dependent paracrine loop. Am J Pathol 1998; 152: 52332.
  • 25
    Raymond MA, Vigneault N, Luyckx V, Hebert MJ. Paracrine repercussions of preconditioning on angiogenesis and apoptosis of endothelial cells. Biochem Biophys Res Commun 2002; 291: 2619.
  • 26
    Kraling BM, Maul GG, Jimenez SA. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995; 63: 4856.
  • 27
    Dieude M, Senecal JL, Rauch J, Hanly JG, Fortin P, Brassard N, et al. Association of autoantibodies to nuclear lamin B1 with thromboprotection in systemic lupus erythematosus: lack of evidence for a direct role of lamin B1 in apoptotic blebs. Arthritis Rheum 2002; 46: 2695707.
  • 28
    Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 131730.
  • 29
    Miranda-Carus ME, Askanase AD, Clancy RM, Di DF, Chou TM, Libera MR, et al. Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-α by macrophages. J Immunol 2000; 165: 534551.
  • 30
    Samejima K, Svingen PA, Basi GS, Kottke T, Mesner PW Jr, Stewart L, et al. Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis. J Biol Chem 1999; 274: 433540.
  • 31
    Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979; 254: 1051422.
  • 32
    Bennett RM, Davis J, Merritt M. Anti-DNA antibodies react with DNA expressed on the surface of monocytes and B lymphocytes. J Rheumatol 1986; 13: 67985.
  • 33
    Bennett RM, Cornell KA, Merritt MJ, Bakke AC, Hsu PH, Hefeneider SH. Autoimmunity to a 28-30 kD cell membrane DNA binding protein: occurrence in selected sera from patients with SLE and mixed connective tissue disease (MCTD). Clin Exp Immunol 1991; 86: 3749.
  • 34
    Misumi Y, Misumi Y, Miki K, Takatsuki A, Tamura G, Ikehara Y. Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J Biol Chem 1986; 261: 11398403.
  • 35
    Harris ML, Rosen A. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 2003; 15: 77884.
  • 36
    Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003; 42: 53440.
  • 37
    Senecal JL, Henault J, Raymond Y. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). J Rheumatol 2005; 32: 16439.
  • 38
    Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001; 70: 369413.
  • 39
    Casiano CA, Martin SJ, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 1996; 184: 76570.
  • 40
    Nguyen VA, Sgonc R, Dietrich H, Wick G. Endothelial injury in internal organs of University of California at Davis line 200 (UCD 200) chickens, an animal model for systemic sclerosis (scleroderma). J Autoimmun 2000; 14: 1439.
  • 41
    Hatakeyama A, Kasturi KN, Wolf I, Phelps RG, Bona CA. Correlation between the concentration of serum anti-topoisomerase I autoantibodies and histological and biochemical alterations in the skin of tight skin mice. Cell Immunol 1996; 167: 13540.
  • 42
    Hu PQ, Fertig N, Medsger TA Jr, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003; 48: 136373.
  • 43
    Weiner ES, Hildebrandt S, Senecal JL, Daniels L, Noell S, Joyal F, et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease: a prospective study. Arthritis Rheum 1991; 34: 6877.
  • 44
    Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000; 43: 107484.
  • 45
    Jacob L, Viard JP, Allenet B, Anin MF, Slama FB, Vandekerckhove J, et al. A monoclonal anti-double-stranded DNA autoantibody binds to a 94-kDa cell-surface protein on various cell types via nucleosomes or a DNA-histone complex. Proc Natl Acad Sci U S A 1989; 86: 466973.